Overview

Nebulizer Delivery of Intranasal Scopolamine

Status:
Not yet recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
To develop a better way to administer anti-motion sickness medications using an intranasal nebulizer.
Phase:
Phase 1
Details
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Treatments:
Butylscopolammonium Bromide
Scopolamine